CVI Investments, Inc. and Heights Capital Management, Inc. filed Amendment No. 4 to Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 83,854 shares of Aptevo Therapeutics Inc. common stock as of September 30, 2026.
Key Highlights
- Triggering event: The date of event requiring this filing was September 30, 2026, according to the filing.
- Shares reported: Both reporting persons each disclosed aggregate beneficial ownership of 83,854 shares of Aptevo Therapeutics common stock, $0.001 par value per share.
- Percent of class: The 83,854 shares represent 4.4% of the class, as stated in the filing.
- Nature of holdings: The filing states the shares reported consist entirely of shares issuable upon the exercise of warrants.
- Voting and dispositive power: Both reporting persons report zero sole voting or dispositive power, and 83,854 shares each of shared voting and shared dispositive power.
- Shares outstanding reference: The filing cites a prospectus indicating 1,810,215 shares outstanding as of August 21, 2026.
CVI Investments and Heights Capital Disclose Warrant-Based Stake in Aptevo Therapeutics
According to the filing, CVI Investments, Inc., organized in the Cayman Islands, and Heights Capital Management, Inc., incorporated in Delaware, jointly submitted Amendment No. 4 to Schedule 13G with respect to their holdings in Aptevo Therapeutics Inc. (NASDAQ:APVO). The filing covers common stock with CUSIP number 03835L702, and the triggering event date is listed as September 30, 2026. The statement was signed by Sarah Travis, Assistant General Counsel and Assistant Secretary, on November 12, 2026.
The filing discloses that the 83,854 shares reported as beneficially owned by each of the two reporting persons consist entirely of shares issuable upon the exercise of warrants. Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and, as such, the filing states it "may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc." The filing further notes that "each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein."
The combined position is listed as 4.4% of the class, with neither reporting person holding any sole voting or sole dispositive power. Item 5 of the filing designates this as ownership of 5 percent or less of a class. The filing references Aptevo Therapeutics' Prospectus (Registration No. 333-298483), filed September 3, 2026, which indicated 1,810,215 shares outstanding as of August 21, 2026. Heights Capital Management acts as the authorized agent of CVI Investments pursuant to a Limited Power of Attorney previously filed with the SEC.
What Was Disclosed
CVI Investments, Inc. and Heights Capital Management, Inc. disclosed a combined beneficial ownership of 83,854 shares, or 4.4%, of Aptevo Therapeutics common stock, held entirely in the form of warrants, as of September 30, 2026, via Amendment No. 4 to Schedule 13G.




Please wait processing your request...